UNION CITY, Calif.--(BUSINESS WIRE)--June 9, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC - News) announced today that it began to ship its new CNS product, Doral® (quazepam), a non-narcotic, selective benzodiazepine receptor agonist that is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The first sales to wholesalers were recorded at the end of May and Questcor’s national sales force will begin detailing the product in the third quarter. James Fares, Questcor’s President and CEO, commented, “We are pleased to have completed the process of converting Doral into a Questcor product and reintroducing it to the market less than a month after we acquired it. We look forward to working with the neurology community to help them understand the many attributes of this important product. We are also excited about our sales force promoting both Acthar Gel® (repository corticotropin injection) and Doral during their visits with professionals in the neurology community.”
